4D Molecular Therapeutics, Inc. Revenue from Related Parties
4D Molecular Therapeutics, Inc. (FDMT) reported Revenue from Related Parties of $0 for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2022-03-28
- 4D Molecular Therapeutics, Inc. revenue from related parties for the quarter ending 2021-09-30 was $0.00.
- 4D Molecular Therapeutics, Inc. revenue from related parties for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. revenue from related parties for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. revenue from related parties for the quarter ending 2020-12-31 was $0.00.
- 4D Molecular Therapeutics, Inc. revenue from related parties for fiscal 2020 was $249.00K, a 857.69% increase from fiscal 2019.
- 4D Molecular Therapeutics, Inc. revenue from related parties for fiscal 2019 was $26.00K.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2022-03-28 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2022-03-28 | $0.00 derived: sum of 4 quarters · filed 2022-03-28 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | $0.00 derived: sum of 2 quarters · filed 2022-03-28 | $0.00 derived: sum of 3 quarters · filed 2022-03-28 | $125.00K derived: sum of 4 quarters · filed 2022-03-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $0.00 derived: sum of 2 quarters · filed 2022-03-28 | $125.00K derived: sum of 3 quarters · filed 2022-03-28 | $249.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $125.00K derived: sum of 2 quarters · filed 2021-11-10 | $249.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $125.00K 10-Q · filed 2021-08-12 | $249.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $124.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $26.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |